A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency

Protocol No
IIT-DHAKAL-VICD-MM
Phase
II
Summary

The purpose of this project is to evaluate if adding another drug, Isatuximab, to a standard induction therapy of Bortezomib, Dexamethasone, and Cyclophosphamide, will help improve the response of patients after receiving subsequent high-dose chemotherapy and ASCT.

Description
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple
Participating Institutions
Froedtert Hospital
Rush University Cancer Center
University of Kansas Medical Center
Status
OPEN TO ACCRUAL